CRSP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
CRISPR Therapeutics AG (CRSP) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, including revenue growth from its Casgevy therapy, potential acquisition speculation, and FDA support for genome-editing therapies. Despite some financial challenges, the company's innovative pipeline and analyst optimism support a long-term investment decision.
The MACD is positive and expanding, indicating bullish momentum. The RSI is in the neutral zone at 79.598, and moving averages are converging, suggesting a potential breakout. The stock closed above its pivot point (54.533) and is near its R1 resistance level (60.022), showing strength. However, post-market activity showed a slight decline (-1.68%).
Strong revenue growth from Casgevy therapy, generating $54 million in Q4 2025 and $116 million for the full year.
Speculation of a potential acquisition by Vertex Pharmaceuticals.
FDA guidance to accelerate the approval of genome-editing therapies.
Casgevy's approval as the first gene-editing therapy for rare blood diseases.
Promising pipeline developments, including zugo-cel and CAR-T therapies.
Financial challenges with a significant YoY revenue drop (-97.58%) in Q4
Negative net income (-$130.6 million) and EPS (-1.37), despite YoY improvement.
Stock trend analysis indicates a potential short-term decline (-0.69% in the next day, -3.14% in the next month).
In Q4 2025, revenue dropped significantly (-97.58% YoY) to $864,000. However, net income improved to -$130.6 million (+250.07% YoY), and EPS increased to -1.37 (+211.36% YoY). Gross margin remained stable at 100%. While revenue decline is concerning, the improvement in net income and EPS indicates better cost management.
Analyst sentiment is mixed but leans positive. Several analysts raised price targets, with Citi at $80, Chardan at $76, and Needham at $82, citing strong Casgevy momentum and pipeline updates. However, Morgan Stanley maintains an Underweight rating with a $33 target. Overall, analysts see potential upside driven by clinical and preclinical developments.
